SEER is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Dysplasia must be present in at least 50% of the cells of at least 2 lines. May occur de novo OR following myelodysplastic/myeloproliferative disorder.
This is an AML with myelodysplasia-related changes. It is an acute leukemia with 20% or more PB or BM blasts with morphologic features of 1. Myelodysplasia OR 2. Prior history of MDS OR 3. Myelodysplastic/myeloproliferative neoplasm OR 4. MDS-related cytopenic abnormalities and without the specific genetic abnormalities of AML with recurrent genetic abnormalities.
These patients DO NOT have a history of prior cytotoxic or radiation therapy for an unrelated disease. The provisional diagnoses during work-up may include refractory anemia with excess blasts; acute erythroid leukemia, acute megakaryoblastic leukemia and AML, NOS.